Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18791402 | 0.85 | SMN1; SMN2 (0.36) | SMN1; SMN2ACHE | |
| SCHEMBL694204 | 0.78 | NOS3 (0.41) | NOS3NOS1NOS2SMN1; SMN2ACHE | |
| SCHEMBL18697135 | 0.77 | NOS3 (0.39) | NOS3NOS1NOS2SMN1; SMN2CYP1A2 | |
| SCHEMBL10144932 | 0.77 | NOS3 (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL21765488 | 0.77 | TDP1 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL23263839 | 0.74 | LMNA (0.38) | SMN1; SMN2 | |
| SCHEMBL21603277 | 0.74 | HPGD (0.43) | SMN1; SMN2ACHE | |
| SCHEMBL29331735 | 0.74 | APP (0.32) | SMN1; SMN2 | |
| SCHEMBL27194684 | 0.74 | TERT (0.33) | NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL4131179 | 0.74 | SMN1; SMN2 (0.30) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257362-A1 | TRIAZOLONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257362-A1 | TRIAZOLONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4166551-A1 | TRIAZOLONE COMPOUND | Medshine Discovery Inc. (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257362-A1 | TRIAZOLONE COMPOUND | WNK3, SLC10A1, WNK2 | NOS3 1405/4885NOS1 2553/4885NOS2 1528/4885 |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | NOS3 3019/4885NOS1 3988/4885NOS2 3349/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | NOS3 1599/4885NOS1 1672/4885NOS2 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.